Výsledky vyhledávání

Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate

Autor: Jeremy O. Jones, Charles J. Ryan, Eric J. Small, C. M. Haqq, Arturo Molina, Won Kim, Marc I. Diamond

Publikováno v: Prostate Cancer and Prostatic Diseases. 17:292-299

Abiraterone acetate (AA), a highly potent CYP17A1 inhibitor, has demonstrated marked clinical benefit in patients with metastatic castration-resistant prostate cancer (CRPC). Phase I trials of AA without prednisone showed significant elevation of ser

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c00430e55ac2b22d61105e491a0bcf88
https://doi.org/10.1038/pcan.2014.27

Zobrazit plný text záznamu

Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy

Autor: Fred Saad, Arturo Molina, Thian Kheoh, Michael Marberger, C. M. Haqq, Karim Fizazi, Kim N. Chi, Peter F.A. Mulders, Jinhui Li, Celestia S. Higano

Publikováno v: European Urology, 65, 875-83
European Urology, 65, 5, pp. 875-83

Item does not contain fulltext BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is a disease that primarily affects older men. Abiraterone acetate (AA), a selective androgen biosynthesis inhibitor, in combination with low-dose pred

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b263a7eccd855faf66a7c935a726ed9
https://doi.org/10.1016/j.eururo.2013.09.005

Zobrazit plný text záznamu

Androgen dynamics and serum PSA in patients treated with abiraterone acetate

Autor: Arturo Molina, C. M. Haqq, Charles J. Ryan, Weimin Peng, D. W. Chandler, Thian Kheoh, Howard I. Scher, E. Welkowsky

Publikováno v: Prostate Cancer and Prostatic Diseases

Background: We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3869550f47da71ec468b271695efaaa
https://doi.org/10.1038/pcan.2014.8

Zobrazit plný text záznamu

Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment

Autor: James Jiao, Robert Stonerock, Caly Chien, Thomas Marbury, Peter Verboven, Jim Breeding, Namphuong Tran, Eric Lawitz, C. M. Haqq, Hans Stieltjes, Martha Gonzalez, Margaret K. Yu, Arturo Molina, Milin Acharya

Publikováno v: The Journal of Clinical Pharmacology. 54:732-741

Three open-label, single-dose studies investigated the impact of hepatic or renal impairment on abiraterone acetate pharmacokinetics and safety/tolerability in non-cancer patients. Patients (n = 8 each group) with mild/moderate hepatic impairment or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9bbf1335eaa50c73035ebc8e945c857
https://doi.org/10.1002/jcph.253

Zobrazit plný text záznamu

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Autor: Scott North, J.S. de Bono, C. M. Haqq, Cora N. Sternberg, Yanni Hao, Karim Fizazi, Dennis D. Gagnon, Margaret Rothman, Thian Kheoh, Howard I. Scher, Charles S. Cleeland, Arturo Molina, Paul N. Mainwaring

Publikováno v: Annals of Oncology. 24:1017-1025

Fatigue is a common, debilitating side-effect of prostate cancer and its treatment. Patient-reported fatigue was evaluated as part of COU-AA-301, a randomized, placebo-controlled, phase III trial of abiraterone acetate and prednisone versus placebo a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180a6d0835e55ac6134b82795c6b953c
https://doi.org/10.1093/annonc/mds585

Zobrazit plný text záznamu

Abstract P2-05-01: Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Autor: Mjm Magbanua, I-Spy Trial Investigators, C. M. Haqq, Christina Yau, L.J. van 't Veer, John W. Park, Sarah E. Davis, Aaron Boudreau, Denise M. Wolf, LJ Esserman

Publikováno v: Cancer Research. 72:P2-05

Background: Prior gene expression profiling studies have identified markers that are predictive of chemotherapy response using pre-treatment biopsies. However, this approach does not account for chemotherapy-induced perturbation in signaling within t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3bf6281d461f306a521fbc26b1fe4168
https://doi.org/10.1158/0008-5472.sabcs12-p2-05-01

Zobrazit plný text záznamu

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial

Autor: Charles J. Ryan, T. Kheoh, Russell P. Grant, Eric J. Small, Arturo Molina, C. M. Haqq, Jinhui Li, Howard I. Scher, Johann S. de Bono

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 31, iss 22

Purpose In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we inves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82feb1d6d11fbe5a560074a783bfec92
https://pubmed.ncbi.nlm.nih.gov/24947249

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání